Evidence map›Paper›PMID 34511330›Full record

ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2021

Proteomic profiling identifies CLEC4C expression as a novel biomarker of primary graft dysfunction after heart transplantation.

Lauren K Truby, Lydia Coulter Kwee, Richa Agarwal, Elizabeth Grass, Adam D DeVore, Chetan B Patel, Dongfeng Chen, Jacob N Schroder, Dawn Bowles, Carmelo A Milano and 2 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Recipient plasma metabolomics as a predictor of heart transplant severe primary graft dysfunction.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. A gentler approach to monitor for heart transplant rejection.Frontiers in cardiovascular medicine · 2024
    Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Lauren K TrubyDepartment of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina; Duke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina.
Lydia Coulter KweeDuke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina.
Richa AgarwalDepartment of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina.
Elizabeth GrassDuke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina.
Adam D DeVoreDepartment of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina.
Chetan B PatelDepartment of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina.
Dongfeng ChenDepartment of Pathology, Duke University School of Medicine, Durham, North Carolina.
Jacob N SchroderDepartment of Surgery, Division of Cardiovascular and Thoracic Surgery, Duke University School of Medicine, Durham, North Carolina.
Dawn BowlesDepartment of Surgery, Division of Cardiovascular and Thoracic Surgery, Duke University School of Medicine, Durham, North Carolina.
Carmelo A MilanoDepartment of Surgery, Division of Cardiovascular and Thoracic Surgery, Duke University School of Medicine, Durham, North Carolina.
Svati H ShahDepartment of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina; Duke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina.
Christopher L HolleyDepartment of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina. Electronic address: cholley@duke.edu.
Duke University · USDuke Medical Center · US

Funding

MULTIDISCIPLINARY HEART &VASCULAR DISEASEST32HL007101 · NHLBI · DUKE UNIVERSITY · PI FREEDMAN, NEIL J. · 1985 to 2020
$9.8M
Postdoctoral Training in Cardiovascular Clinical ResearchT32HL069749 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2003 to 2023
$6.7M
NHLBI NIH HHS L30 HL154239NHLBI NIH HHS T32 HL007101NHLBI NIH HHS T32 HL069749
6 · The paper itself

Abstract

purposeClinical models to identify patients at high risk of primary graft dysfunction (PGD) after heart transplantation (HT) are limited, and the underlying pathophysiology of this common post-transplant complication remains poorly understood. We sought to identify whether pre-transplant levels of circulating proteins reporting on immune activation and inflammation are associated with incident PGD.

methodsThe study population consisted of 219 adult heart transplant recipients identified between 2016 and 2020 at Duke University Medical Center, randomly divided into derivation (n = 131) and validation (n = 88) sets. PGD was defined using modified ISHLT criteria. Proteomic profiling was performed using Olink panels (n = 354 proteins) with serum samples collected immediately prior to transplantation. Association between normalized relative protein expression and PGD was tested using univariate and multivariable (recipient age, creatinine, mechanical circulatory support, and sex; donor age; ischemic time) models. Significant proteins identified in the derivation set (p < 0.05 in univariate models), were then tested in the validation set. Pathway enrichment analysis was used to test candidate biological processes. The predictive performance of proteins was compared to that of the RADIAL score.

resultsNine proteins were associated with PGD in univariate models in the derivation set. Of these, only CLEC4C remained associated with PGD in the validation set after Bonferroni correction (OR [95% CI] = 3.04 [1.74,5.82], p = 2.8 × 10

conclusionsPre-transplantation circulating levels of CLEC4C, a protein marker of plasmacytoid dendritic cells (pDCs), may identify HT recipients at risk for PGD. Further studies are needed to better understand the potential role pDCs and the innate immune response in PGD.

Indexed as

AgedAged, 80 and overBiomarkersCardiomyopathiesFemaleHeart TransplantationHumansLectins, C-TypeMaleMembrane GlycoproteinsMiddle AgedPostoperative ComplicationsPrimary Graft DysfunctionProteomicsReceptors, ImmunologicSensitivity and SpecificityBiomarkersCLEC4C protein, humanLectins, C-TypeMembrane GlycoproteinsReceptors, Immunologicheart transplantinnate immunityplasmacytoid dendritic cellprimary graft dysfunctionproteomics

Identifiers

PMID34511330
PMCPMC8670564
OpenAlexW3191428344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.